The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD

The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD

Salepage : The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD

Arichive : The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD

Faculty:

Michael Mithoefer, MD

Duration:

1 Hour 30 Minutes

Format:

Audio and Video

Copyright:

May 28, 2021 

Product Code:

POS052733

Media Type:

Digital Seminar

As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favorable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this workshop by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:

• The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy
• The MDMA-assisted psychotherapy process, illustrated with video clips
• How these inner-directed approaches to therapy respect and support clients’ innate healing intelligence
• New opportunities for psychotherapists to receive training in this approach

Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel. 

Speaker Disclosures:

Financial: Dr. Michael Mithoefer has employment relationships with the Medical University of South Carolina and the Multidisciplinary Association for Psychedelic Studies. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.

Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.